What novel medication options are recommended for treatment‑resistant depression?

Novel Medications for Treatment-Resistant Depression

For treatment-resistant depression, esketamine (intranasal) is the only FDA-approved novel medication specifically indicated for TRD and should be used as adjunctive therapy with an oral antidepressant, while second-generation antipsychotics (aripiprazole, brexpiprazole) represent established augmentation options. 1, 2

Primary Novel Medication: Esketamine

Intranasal esketamine (Spravato) is FDA-approved specifically for TRD and demonstrates rapid reduction in depressive symptoms within hours to days, unlike traditional antidepressants that require weeks. 2

Administration Protocol

• Self-administered intranasally under healthcare provider supervision 2
• Requires 2-hour post-dose monitoring for sedation, dizziness, dissociation reactions, and blood pressure elevations 2
• Used as adjunct to oral antidepressant therapy, not as monotherapy 2
• Adverse effects are primarily confined to the 2-hour monitoring window 2

Evidence Strength

The rapid-acting antidepressant properties of ketamine/esketamine have been confirmed through multiple randomized placebo-controlled trials, with effect sizes as high as d = 2.36 at 40 minutes in patients with high baseline suicidal ideation. 3 Recent expert consensus from the Mayo Clinic Depression Center strongly recommends ketamine/esketamine as a next-step treatment option for TRD. 4

Established Augmentation Strategies

Second-generation antipsychotics, particularly aripiprazole and brexpiprazole, are strongly recommended as augmentation agents for TRD based on current guidelines and expert consensus. 1, 4

• Aripiprazole and brexpiprazole function as partial dopamine agonists with proven efficacy in TRD 5
• These agents received strong consensus as next-step treatments in recent expert panel recommendations 4
• Dosing should be individualized, with metabolic monitoring required (particularly for olanzapine and clozapine, which warrant metformin co-prescription) 1

Emerging Novel Mechanisms Under Investigation

Glutamate System Modulators

Beyond esketamine, multiple glutamate-targeting compounds are in Phase II-III trials, including NMDA receptor antagonists, AMPA receptor modulators, and mGlu5 receptor antagonists. 6, 7

Psychedelic Compounds

Psilocybin has seen the greatest surge in clinical investigation over the past 5 years, with multiple trials ongoing for TRD. 7 However, these agents lack regulatory approval and remain investigational.

Opioidergic System Modulators

Kappa opioid receptor antagonists represent a promising novel target, though clinical development is still in early phases. 6

Critical Treatment Selection Factors

Treatment selection must account for specific patient characteristics beyond simple treatment failure count:

• Metabolic disease: Shifts preference away from certain antipsychotics toward esketamine or non-augmentative strategies 4
• Age considerations: Older adults (>65 years) require starting doses at approximately 50% of standard adult dosing 1
• Comorbid anxiety or substance use disorders: These comorbidities are 1.85-3.12 times more prevalent in TRD and may influence treatment selection 8
• Suicidal ideation: Ketamine demonstrates rapid antisuicidal effects independent of general antidepressant response, with benefits emerging within 40 minutes 3

Common Pitfalls to Avoid

• Premature discontinuation: Increases relapse risk substantially 1
• Inadequate dosing: Failure to titrate to therapeutic doses contributes to suboptimal outcomes 1
• Insufficient trial duration: Clinical response should be assessed at 1-2 weeks, but regimen modification should not occur before 6-8 weeks unless safety concerns arise 1
• Monotherapy with novel agents: Esketamine must be used as adjunctive therapy, not alone 2
• Inadequate monitoring: The 2-hour post-esketamine monitoring period is mandatory for safety 2

Alternative Interventional Approaches

When pharmacologic options prove insufficient, transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT) represent evidence-based non-pharmacologic interventions with strong expert consensus support. 9, 4 ECT remains the most efficacious antidepressant treatment overall, though onset of antisuicidal effects may require 1-2 weeks. 3